BRPI0808421A2 - Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula. - Google Patents
Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula.Info
- Publication number
- BRPI0808421A2 BRPI0808421A2 BRPI0808421A BRPI0808421A2 BR PI0808421 A2 BRPI0808421 A2 BR PI0808421A2 BR PI0808421 A BRPI0808421 A BR PI0808421A BR PI0808421 A2 BRPI0808421 A2 BR PI0808421A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- inducing
- cytotoxic
- exosome
- vaccine
- Prior art date
Links
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title 2
- 230000001939 inductive effect Effects 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000000612 antigen-presenting cell Anatomy 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 210000004027 cell Anatomy 0.000 title 1
- 210000001808 exosome Anatomy 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000035755 proliferation Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464422—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464434—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464462—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122020021065-6A BR122020021065B1 (pt) | 2007-02-21 | 2008-02-21 | Composição farmacêutica e vacina à base de peptídeos para antígenos associados a tumores expressando câncer, exossomo, método in vitro para induzir células apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica e uso de um peptídeo |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90294907P | 2007-02-21 | 2007-02-21 | |
US60/902,949 | 2007-02-21 | ||
PCT/JP2008/000290 WO2008102557A1 (en) | 2007-02-21 | 2008-02-21 | Peptide vaccines for cancers expressing tumor-associated antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0808421A2 true BRPI0808421A2 (pt) | 2017-08-29 |
BRPI0808421B1 BRPI0808421B1 (pt) | 2021-10-05 |
Family
ID=39709837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0808421-1A BRPI0808421B1 (pt) | 2007-02-21 | 2008-02-21 | Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula |
Country Status (28)
Country | Link |
---|---|
EP (20) | EP2476693B1 (pt) |
JP (6) | JP5239103B2 (pt) |
KR (8) | KR20160045939A (pt) |
CN (4) | CN102863514B (pt) |
AR (1) | AR068302A1 (pt) |
AU (1) | AU2008218463B2 (pt) |
BR (1) | BRPI0808421B1 (pt) |
CA (3) | CA2992074C (pt) |
CO (1) | CO6190536A2 (pt) |
CY (2) | CY1114590T1 (pt) |
DK (3) | DK2121731T3 (pt) |
ES (6) | ES2540893T3 (pt) |
HK (7) | HK1172043A1 (pt) |
HR (3) | HRP20131044T1 (pt) |
IL (10) | IL200478A (pt) |
MX (4) | MX2009009022A (pt) |
MY (2) | MY173379A (pt) |
NZ (4) | NZ591704A (pt) |
PH (1) | PH12014501642A1 (pt) |
PL (3) | PL2121731T3 (pt) |
PT (2) | PT2121731E (pt) |
RU (1) | RU2464275C2 (pt) |
SG (3) | SG10201909675QA (pt) |
SI (3) | SI2121731T1 (pt) |
TW (5) | TWI615403B (pt) |
UA (1) | UA100372C2 (pt) |
WO (1) | WO2008102557A1 (pt) |
ZA (1) | ZA200905881B (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1660677A2 (en) | 2003-08-20 | 2006-05-31 | Oncotherapy Science, Inc. | Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc) |
JP5294271B2 (ja) | 2007-08-20 | 2013-09-18 | オンコセラピー・サイエンス株式会社 | Cdh3ペプチド及びこれを含む薬剤 |
RU2011103199A (ru) | 2008-06-30 | 2012-08-10 | Онкотерапи Сайенс, Инк. (Jp) | Антитела против cdh3, меченные радиоизотопной меткой, и их применение |
TWI543767B (zh) * | 2008-08-19 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗 |
TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
KR101705150B1 (ko) * | 2008-10-22 | 2017-02-22 | 온코세라피 사이언스 가부시키가이샤 | Rab6kifl/kif20a 에피토프 펩티드 및 이를 포함하는 백신 |
TWI500932B (zh) * | 2008-12-05 | 2015-09-21 | Oncotherapy Science Inc | Wdrpuh抗原決定位胜肽以及含此胜肽之疫苗 |
WO2010073551A1 (en) | 2008-12-24 | 2010-07-01 | Oncotherapy Science, Inc. | C1orf59 peptides and vaccines including the same |
TW201102081A (en) | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
US8703808B2 (en) | 2009-06-23 | 2014-04-22 | Centre National De La Recherche Scientifique | Use of derivatives of indoles for the treatment of cancer |
EP3450459B1 (en) | 2009-12-28 | 2021-05-26 | OncoTherapy Science, Inc. | Anti-cdh3 antibodies and uses thereof |
DK2547359T3 (en) | 2010-03-15 | 2016-06-06 | The Board Of Trustees Of The Univ Of Illionis | Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS |
TW201627003A (zh) * | 2010-04-02 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Ect2胜肽及含此胜肽之疫苗 |
JP6064186B2 (ja) * | 2010-12-02 | 2017-01-25 | オンコセラピー・サイエンス株式会社 | Tomm34ペプチドおよびそれを含むワクチン |
WO2013090732A2 (en) | 2011-12-14 | 2013-06-20 | The Board Of Regents Of The University Of Texas System | Collateral gene inactivation biomarkers and targets for cancer therapy |
EP2823824A4 (en) | 2012-03-09 | 2015-09-16 | Oncotherapy Science Inc | PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE |
EP2872531A4 (en) | 2012-07-10 | 2016-04-06 | Oncotherapy Science Inc | LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME |
WO2014010231A1 (en) | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Kif20a epitope peptides for th1 cells and vaccines containing the same |
WO2014034754A1 (ja) * | 2012-08-31 | 2014-03-06 | 塩野義製薬株式会社 | Psf1由来ペプチド |
AU2013317194B2 (en) * | 2012-09-11 | 2018-07-12 | Oncotherapy Science, Inc. | UBE2T peptides and vaccines containing the same |
WO2014141652A1 (en) * | 2013-03-11 | 2014-09-18 | Oncotherapy Science, Inc. | Smyd3 peptides and vaccines containing the same |
TWI658049B (zh) * | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Kntc2胜肽及含此胜肽之疫苗 |
JPWO2015005479A1 (ja) * | 2013-07-12 | 2017-03-02 | 大日本住友製薬株式会社 | 腫瘍抗原ペプチド |
JP2015227292A (ja) * | 2014-05-30 | 2015-12-17 | 国立大学法人高知大学 | 膵がん細胞浸潤転移抑制ワクチン |
EP3164417A1 (en) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
RU2700881C2 (ru) * | 2014-08-04 | 2019-09-23 | Онкотерапи Сайенс, Инк. | Пептид, полученный из urlc10, и содержащая его вакцина |
GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
CN104975082B (zh) * | 2015-06-05 | 2018-11-02 | 复旦大学附属肿瘤医院 | 一组用于评估肺癌预后的基因及其应用 |
MA44524A (fr) * | 2016-03-31 | 2019-02-06 | Neon Therapeutics Inc | Néoantigènes et leurs procédés d'utilisation |
WO2018090257A1 (zh) * | 2016-11-16 | 2018-05-24 | 深圳华大基因研究院 | 多肽及其应用 |
US11325959B2 (en) | 2017-01-25 | 2022-05-10 | Ose Immunotherapeutics | Method for manufacturing a stable emulsion for peptide delivery |
JP7289289B2 (ja) * | 2017-03-28 | 2023-06-09 | ツェンラン・チュー | 腫瘍性疾患を治療する方法 |
US11918634B2 (en) * | 2017-08-10 | 2024-03-05 | Good T Cells, Inc. | Method for activating T cells for cancer treatment |
WO2019160099A1 (ja) * | 2018-02-15 | 2019-08-22 | 大塚製薬株式会社 | がん抗原ペプチド |
KR102335916B1 (ko) * | 2019-04-22 | 2021-12-08 | 한국과학기술연구원 | 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
KR102322832B1 (ko) * | 2019-04-22 | 2021-11-12 | 한국과학기술연구원 | 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
NZ231899A (en) * | 1985-10-03 | 1991-07-26 | Genentech Inc | Human or porcine inhibin peptide compositions and dna encoding them |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
IL103928A0 (en) * | 1991-12-11 | 1993-04-04 | American Home Prod | Expression of specific immunogens using viral antigens |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
AU702522B2 (en) * | 1994-04-15 | 1999-02-25 | Amgen, Inc. | HEK5, HEK7, HEK8, HEK11, new EPH-like receptor protein tyrosine kinases |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
US20030198642A1 (en) | 1995-08-03 | 2003-10-23 | Johannes J. Geuze | Cell derived antigen presenting vesicles |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
EP0960204A4 (en) | 1996-07-26 | 2002-01-23 | Sloan Kettering Inst Cancer | METHODS AND REAGENTS FOR GENETIC IMMUNIZATION |
WO1998045433A1 (en) * | 1997-04-04 | 1998-10-15 | Board Of Regents, The University Of Texas System | Proteins and compositions for modulating mitosis |
FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
WO1999018126A1 (fr) * | 1997-10-07 | 1999-04-15 | Ono Pharmaceutical Co., Ltd. | POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION |
US20070014787A1 (en) * | 1998-07-15 | 2007-01-18 | Human Genome Sciences, Inc. | 71 human secreted proteins |
WO2001029221A2 (en) * | 1999-10-20 | 2001-04-26 | Zymogenetics, Inc. | Proteins and polynucleotides encoding them |
US6682902B2 (en) * | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
US20030013649A1 (en) * | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
CN1469926A (zh) * | 2000-03-29 | 2004-01-21 | 科里克萨有限公司 | 治疗和诊断肺癌的组合物和方法 |
AU2001278076A1 (en) | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-5 proteins and related reagents and methods of use thereof |
US6830885B1 (en) * | 2000-08-18 | 2004-12-14 | Phenogene Therapeutiques Inc. | Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature |
US20090062512A1 (en) * | 2000-10-10 | 2009-03-05 | Hildebrand William H | Comparative ligand mapping from MHC class I positive cells |
US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
CN100400099C (zh) * | 2001-01-04 | 2008-07-09 | 北京迪威华宇生物技术有限公司 | 预防和治疗人前列腺癌的重组蛋白疫苗 |
AU2002311787A1 (en) * | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
AU2002309583A1 (en) * | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
EP1517998A2 (en) * | 2001-06-18 | 2005-03-30 | EOS Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20030124579A1 (en) * | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
WO2003080640A1 (en) * | 2002-03-07 | 2003-10-02 | Ludwig Institute For Cancer Research | Lymphatic and blood endothelial cell genes |
US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
US20070015271A1 (en) * | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
CA2500687A1 (en) * | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20040224408A1 (en) * | 2002-12-10 | 2004-11-11 | Jean-Philippe Girard | THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation |
AU2003297318A1 (en) * | 2002-12-20 | 2004-07-22 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. |
TWI324608B (en) * | 2003-02-28 | 2010-05-11 | Oncotherapy Science Inc | Genes and polypeptides relating to human colorectal cancers |
EP1651775A2 (en) * | 2003-06-18 | 2006-05-03 | Arcturus Bioscience, Inc. | Breast cancer survival and recurrence |
WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP1660677A2 (en) * | 2003-08-20 | 2006-05-31 | Oncotherapy Science, Inc. | Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc) |
US20070253954A1 (en) * | 2004-02-27 | 2007-11-01 | Oncotherapy Science, Inc. | Epha4 As Therapeutic Target Of Prc And Pdaca |
EP2520652B1 (en) * | 2004-04-09 | 2015-06-10 | Genecare Research Institute Co., Ltd | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes |
CA2566506A1 (en) * | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
CN100381460C (zh) * | 2004-11-30 | 2008-04-16 | 北京市肿瘤防治研究所 | Her-2模拟抗原表位及含有该表位的肽 |
RU2007135030A (ru) * | 2005-02-24 | 2009-03-27 | Симайнз, Инк. (Us) | Композиции и способы классификации биологических образцов |
WO2006090810A2 (en) * | 2005-02-25 | 2006-08-31 | Oncotherapy Science, Inc. | Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides |
CN100348614C (zh) * | 2005-06-03 | 2007-11-14 | 北京大学 | 一种肝癌-睾丸特异性抗原蛋白质和抗原肽 |
ES2373055T3 (es) * | 2005-08-09 | 2012-01-31 | Oncotherapy Science, Inc. | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. |
US8030443B2 (en) * | 2005-08-09 | 2011-10-04 | Kurume University | Squamous cell carcinoma antigen-derived peptide binding to HLA-A24 molecule |
WO2007032255A1 (ja) | 2005-09-13 | 2007-03-22 | Mie University | T細胞レセプター及び該レセプターをコードする核酸 |
US20090263832A1 (en) * | 2005-11-30 | 2009-10-22 | Roberto Polakiewicz | Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways |
CN101467039B (zh) * | 2006-04-10 | 2013-11-06 | 健泰科生物技术公司 | 散乱蛋白pdz调节剂 |
JP5150849B2 (ja) * | 2006-06-16 | 2013-02-27 | オンコセラピー・サイエンス株式会社 | Sparc由来の癌拒絶抗原ペプチド及びこれを含む医薬 |
US20090081659A1 (en) * | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
EP1983003A3 (en) * | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
JP5294271B2 (ja) * | 2007-08-20 | 2013-09-18 | オンコセラピー・サイエンス株式会社 | Cdh3ペプチド及びこれを含む薬剤 |
EP2080812A1 (en) * | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
TWI543767B (zh) * | 2008-08-19 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗 |
WO2011039289A1 (de) * | 2009-09-29 | 2011-04-07 | Protagen Ag | Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung |
-
2008
- 2008-02-18 TW TW105108412A patent/TWI615403B/zh active
- 2008-02-18 TW TW104120673A patent/TWI596109B/zh not_active IP Right Cessation
- 2008-02-18 TW TW103107156A patent/TWI610939B/zh active
- 2008-02-18 TW TW097105594A patent/TWI438207B/zh not_active IP Right Cessation
- 2008-02-18 TW TW103114624A patent/TWI494319B/zh not_active IP Right Cessation
- 2008-02-21 EP EP12151714.8A patent/EP2476693B1/en active Active
- 2008-02-21 EP EP12175489.9A patent/EP2594582A3/en not_active Withdrawn
- 2008-02-21 BR BRPI0808421-1A patent/BRPI0808421B1/pt not_active IP Right Cessation
- 2008-02-21 NZ NZ591704A patent/NZ591704A/xx not_active IP Right Cessation
- 2008-02-21 MX MX2009009022A patent/MX2009009022A/es active IP Right Grant
- 2008-02-21 EP EP12175483.2A patent/EP2570430A3/en not_active Withdrawn
- 2008-02-21 SG SG10201909675Q patent/SG10201909675QA/en unknown
- 2008-02-21 ES ES12151722.1T patent/ES2540893T3/es active Active
- 2008-02-21 AR ARP080100718A patent/AR068302A1/es unknown
- 2008-02-21 KR KR1020167010159A patent/KR20160045939A/ko not_active Application Discontinuation
- 2008-02-21 PL PL08710443T patent/PL2121731T3/pl unknown
- 2008-02-21 SG SG10201506589WA patent/SG10201506589WA/en unknown
- 2008-02-21 CN CN201210352621.7A patent/CN102863514B/zh active Active
- 2008-02-21 RU RU2009135020/10A patent/RU2464275C2/ru active
- 2008-02-21 KR KR1020157002221A patent/KR101644877B1/ko active IP Right Grant
- 2008-02-21 EP EP12175478A patent/EP2565203A1/en not_active Withdrawn
- 2008-02-21 CA CA2992074A patent/CA2992074C/en active Active
- 2008-02-21 KR KR1020137004417A patent/KR101511140B1/ko active IP Right Grant
- 2008-02-21 SI SI200831053T patent/SI2121731T1/sl unknown
- 2008-02-21 EP EP12151711.4A patent/EP2465864B1/en not_active Not-in-force
- 2008-02-21 EP EP12151722.1A patent/EP2465867B1/en active Active
- 2008-02-21 PT PT87104436T patent/PT2121731E/pt unknown
- 2008-02-21 KR KR1020147026715A patent/KR101540000B1/ko active IP Right Grant
- 2008-02-21 NZ NZ602119A patent/NZ602119A/en not_active IP Right Cessation
- 2008-02-21 EP EP12175487.3A patent/EP2573110A3/en not_active Withdrawn
- 2008-02-21 WO PCT/JP2008/000290 patent/WO2008102557A1/en active Application Filing
- 2008-02-21 KR KR1020157026286A patent/KR20150116463A/ko active IP Right Grant
- 2008-02-21 NZ NZ602122A patent/NZ602122A/en not_active IP Right Cessation
- 2008-02-21 SI SI200831332T patent/SI2465864T1/sl unknown
- 2008-02-21 KR KR1020147026728A patent/KR101543623B1/ko active IP Right Grant
- 2008-02-21 KR KR1020157013656A patent/KR101644871B1/ko active IP Right Grant
- 2008-02-21 EP EP12151717.1A patent/EP2476694B1/en active Active
- 2008-02-21 PL PL12151717T patent/PL2476694T3/pl unknown
- 2008-02-21 PL PL12151711T patent/PL2465864T3/pl unknown
- 2008-02-21 EP EP12151705.6A patent/EP2476692B1/en not_active Not-in-force
- 2008-02-21 JP JP2009534784A patent/JP5239103B2/ja active Active
- 2008-02-21 AU AU2008218463A patent/AU2008218463B2/en active Active
- 2008-02-21 EP EP12175488.1A patent/EP2583976A3/en not_active Withdrawn
- 2008-02-21 EP EP12175490.7A patent/EP2574623A3/en not_active Withdrawn
- 2008-02-21 CN CN201310183458.0A patent/CN103351423B/zh active Active
- 2008-02-21 DK DK08710443.6T patent/DK2121731T3/da active
- 2008-02-21 EP EP12175481.6A patent/EP2570428A3/en not_active Withdrawn
- 2008-02-21 DK DK12151717.1T patent/DK2476694T3/en active
- 2008-02-21 MY MYPI2012004306A patent/MY173379A/en unknown
- 2008-02-21 MX MX2013009905A patent/MX337456B/es unknown
- 2008-02-21 PT PT121517114T patent/PT2465864E/pt unknown
- 2008-02-21 SI SI200831368T patent/SI2476694T1/sl unknown
- 2008-02-21 MX MX2016002567A patent/MX359680B/es unknown
- 2008-02-21 DK DK12151711.4T patent/DK2465864T3/en active
- 2008-02-21 ES ES12151714.8T patent/ES2532708T3/es active Active
- 2008-02-21 CN CN200880012937.3A patent/CN101663315B/zh active Active
- 2008-02-21 MX MX2013009906A patent/MX337417B/es unknown
- 2008-02-21 EP EP12151720A patent/EP2465866A3/en not_active Withdrawn
- 2008-02-21 CA CA2678755A patent/CA2678755C/en active Active
- 2008-02-21 EP EP12151719.7A patent/EP2465865B1/en not_active Not-in-force
- 2008-02-21 CN CN201410449753.0A patent/CN104292299B/zh active Active
- 2008-02-21 ES ES08710443T patent/ES2435194T3/es active Active
- 2008-02-21 CA CA2919248A patent/CA2919248A1/en not_active Abandoned
- 2008-02-21 EP EP12151723A patent/EP2476695A3/en not_active Withdrawn
- 2008-02-21 ES ES12151711.4T patent/ES2527397T3/es active Active
- 2008-02-21 EP EP12175480.8A patent/EP2567971A3/en not_active Withdrawn
- 2008-02-21 ES ES12151717T patent/ES2530777T3/es active Active
- 2008-02-21 EP EP08710443.6A patent/EP2121731B1/en active Active
- 2008-02-21 EP EP12175484.0A patent/EP2594581A3/en not_active Withdrawn
- 2008-02-21 EP EP12175482.4A patent/EP2570429A3/en not_active Withdrawn
- 2008-02-21 UA UAA200909469A patent/UA100372C2/ru unknown
- 2008-02-21 MY MYPI20093446A patent/MY155029A/en unknown
- 2008-02-21 ES ES12151705.6T patent/ES2541863T3/es active Active
- 2008-02-21 KR KR1020097019583A patent/KR101511134B1/ko active IP Right Grant
- 2008-02-21 EP EP12175479.0A patent/EP2573109A3/en not_active Withdrawn
- 2008-02-21 NZ NZ579768A patent/NZ579768A/en not_active IP Right Cessation
- 2008-02-21 SG SG2012012126A patent/SG179402A1/en unknown
-
2009
- 2009-08-18 IL IL200478A patent/IL200478A/en active IP Right Grant
- 2009-08-25 ZA ZA200905881A patent/ZA200905881B/xx unknown
- 2009-09-21 CO CO09102283A patent/CO6190536A2/es not_active Application Discontinuation
-
2010
- 2010-02-02 JP JP2010021234A patent/JP5239104B2/ja active Active
- 2010-03-10 HK HK12112899.3A patent/HK1172043A1/xx not_active IP Right Cessation
- 2010-03-10 HK HK12112898.4A patent/HK1172042A1/zh not_active IP Right Cessation
- 2010-03-10 HK HK12112897.5A patent/HK1172041A1/xx not_active IP Right Cessation
- 2010-03-10 HK HK10102517.8A patent/HK1134507A1/xx not_active IP Right Cessation
- 2010-03-10 HK HK12112988.5A patent/HK1172345A1/xx not_active IP Right Cessation
- 2010-03-10 HK HK12112987.6A patent/HK1172344A1/xx not_active IP Right Cessation
- 2010-03-10 HK HK12112989A patent/HK1172346A1/xx not_active IP Right Cessation
-
2012
- 2012-04-04 IL IL219041A patent/IL219041A/en not_active IP Right Cessation
- 2012-04-04 IL IL219046A patent/IL219046A/en not_active IP Right Cessation
- 2012-04-04 IL IL219043A patent/IL219043A/en not_active IP Right Cessation
- 2012-04-04 IL IL219040A patent/IL219040A/en active IP Right Grant
- 2012-04-04 IL IL219045A patent/IL219045A0/en unknown
- 2012-04-04 IL IL219047A patent/IL219047A0/en unknown
- 2012-04-04 IL IL219044A patent/IL219044A/en active IP Right Grant
- 2012-04-04 IL IL219048A patent/IL219048A/en not_active IP Right Cessation
- 2012-04-04 IL IL219042A patent/IL219042A/en not_active IP Right Cessation
- 2012-11-29 JP JP2012260412A patent/JP5614761B2/ja active Active
- 2012-11-29 JP JP2012260421A patent/JP5608953B2/ja active Active
-
2013
- 2013-11-05 HR HRP20131044AT patent/HRP20131044T1/hr unknown
- 2013-11-08 CY CY20131100994T patent/CY1114590T1/el unknown
-
2014
- 2014-07-17 PH PH12014501642A patent/PH12014501642A1/en unknown
- 2014-07-24 JP JP2014150295A patent/JP5874158B2/ja not_active Expired - Fee Related
- 2014-12-17 HR HRP20141233AT patent/HRP20141233T1/hr unknown
- 2014-12-18 CY CY20141101067T patent/CY1115841T1/el unknown
-
2015
- 2015-01-28 HR HRP20150108TT patent/HRP20150108T1/hr unknown
- 2015-12-25 JP JP2015252737A patent/JP2016094459A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0808421A2 (pt) | Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula. | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
CL2011001536A1 (es) | Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
CL2008001540A1 (es) | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
CL2008001076A1 (es) | Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2011001232A1 (es) | Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer | |
CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
BR112015014969A2 (pt) | micromatriz para entrega de agente terapêutico e métodos de uso | |
CL2007003202A1 (es) | Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular. | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
CL2012002606A1 (es) | Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales. | |
CL2008002243A1 (es) | Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2010001483A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune. | |
CL2007000311A1 (es) | Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer. | |
MX2009008926A (es) | Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1. | |
CL2007002234A1 (es) | Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas. | |
CL2011000301A1 (es) | Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer. | |
BRPI0810524A2 (pt) | Derivado de (aza)indol e uso do mesmo para propósitos médicos | |
CL2007003552A1 (es) | Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular. | |
CL2007001435A1 (es) | Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer. | |
ECSP088752A (es) | Formulaciones para administración parenteral de compuestos y sus usos | |
CL2008002381A1 (es) | Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer. | |
CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/02/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2762 DE 12-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |